The AMEND TS Early Feasibility Study is a Prospective, Single-arm, Multi-center Study to Evaluate the Safety and Function of the AMEND(TM) Trans-Septal System for MR Reduction: Up to 15 Subjects Will be Enrolled in up to 7 Investigational Centers in the U.S. and Canada With a 30d Safety Endpoint

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Mitral Regurgitation FunctionalMitral IncompetenceAnnuloplasty
Interventions
DEVICE

This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.

The ability to deploy the annuloplasty ring in a percutaneous fashion affords an improved safety profile for surgical candidates, as well as surgical style solution for those patients that are at elevated risk for surgery due to comorbidities and advanced age. This early feasibility study allows treatment of higher risk surgical candidates with a surgical- level annuloplasty repair therapy by the AMEND™ Implant.

Trial Locations (2)

10032

'Nyph/Cuimc', New York

19801

Valcare Medical Inc., Wilmington

All Listed Sponsors
lead

Valcare Medical Ltd.

INDUSTRY

NCT06951672 - The AMEND TS Early Feasibility Study is a Prospective, Single-arm, Multi-center Study to Evaluate the Safety and Function of the AMEND(TM) Trans-Septal System for MR Reduction: Up to 15 Subjects Will be Enrolled in up to 7 Investigational Centers in the U.S. and Canada With a 30d Safety Endpoint | Biotech Hunter | Biotech Hunter